|
LATS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62658775337832E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.63380420303838E-12 |
| Normal-vs-Stage2 |
1.94270155517984E-11 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
2.326400E-01 |
| Stage1-vs-Stage3 |
2.339700E-02 |
| Stage1-vs-Stage4 |
3.90030000000374E-05 |
| Stage2-vs-Stage3 |
7.597600E-03 |
| Stage2-vs-Stage4 |
2.031800E-04 |
| Stage3-vs-Stage4 |
1.296020E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.7715611723761E-16 |
| Normal-vs-AfricanAmerican |
4.26950000020909E-07 |
| Normal-vs-Asian |
5.55111512312578E-16 |
| Caucasian-vs-AfricanAmerican |
8.190000E-02 |
| Caucasian-vs-Asian |
5.984600E-01 |
| AfricanAmerican-vs-Asian |
1.092550E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62525548574877E-12 |
| Normal-vs-Female |
1.62736490949555E-12 |
| Male-vs-Female |
5.000200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.77395900588817E-15 |
| Normal-vs-Age(41-60Yrs) |
1.62669877568078E-12 |
| Normal-vs-Age(61-80Yrs) |
6.66133814775094E-16 |
| Normal-vs-Age(81-100Yrs) |
9.5333999999947E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.165000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.800000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.952400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.080600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.031200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.480400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.04590000391281E-08 |
| Classical-VS-Follicular |
3.405700E-02 |
| Classical-VS-Other |
6.390200E-01 |
| Classical-VS-Normal |
1.73194791841524E-14 |
| Tall-VS-Follicular |
7.41450001395805E-09 |
| Tall-VS-Other |
4.158500E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
2.873200E-01 |
| Follicular-VS-Normal |
1.02380326438833E-11 |
| Other-VS-Normal |
4.25169999984654E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.44249065417534E-15 |
| Normal-vs-N1 |
3.33066907387547E-16 |
| N0-vs-N1 |
1.823790E-01 |
|
|
